An ApoA‐I Mimetic Peptide High‐Density‐Lipoprotein‐Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection | Zendy

Cormode David P. | Zendy; BrileySaebo Karen C. | Zendy; Mulder Willem J. M. | Zendy; Aguinaldo Juan Gilberto S. | Zendy; Barazza Alessandra | Zendy; Ma Yanqing | Zendy; Fisher Edward A. | Zendy; Fayad Zahi A. | Zendy

Premium

An ApoA‐I Mimetic Peptide High‐Density‐Lipoprotein‐Based MRI Contrast Agent for Atherosclerotic Plaque Composition Detection

Author(s) -

Cormode David P.,

BrileySaebo Karen C.,

Mulder Willem J. M.,

Aguinaldo Juan Gilberto S.,

Barazza Alessandra,

Ma Yanqing,

Fisher Edward A.,

Fayad Zahi A.

Publication year - 2008

Publication title -

small

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.785

H-Index - 236

eISSN - 1613-6829

pISSN - 1613-6810

DOI - 10.1002/smll.200701285

Subject(s) - confocal , lipoprotein , contrast (vision) , confocal microscopy , cholesterol , nanoparticle , chemistry , pathology , medicine , materials science , nanotechnology , biochemistry , biology , microbiology and biotechnology , computer science , geometry , mathematics , artificial intelligence

Cardiovascular disease is one of the prime causes of mortality throughout the world and there is a need for targeted and effective contrast agents to allow noninvasive imaging of the cholesterol‐rich atherosclerotic plaques in arteries. A new, fully synthetic, high‐density lipoprotein (HDL)‐mimicking MRI contrast agent is developed, which enhances macrophage‐rich areas of plaque in a mouse model of atherosclerosis by 94%. Confirmation of the targeting of this nanoparticulate agent is achieved using confocal microscopy by tracking a fluorescent lipid incorporated into the nanoparticle.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research